Tamoxifen (Nolvadex)

DRUG4 trials

Sponsors

AstraZeneca, Ente Ospedaliero Ospedali Galliera, Rutgers, The State University of New Jersey

Conditions

Breast CancerBreast Cancer InvasiveHigh Risk for Invasive Breast Cancer

Phase 2

SHORTened Duration of TAMoxifen

Active, not recruitingNCT07806630

Rutgers, The State University of New JerseyHigh Risk for Invasive Breast Cancer

Start: 2026-09-01End: 2029-07-01Target: 250Updated: 2026-09-08

Phase 3

ATAC - Endometrial Sub-Protocol

CompletedNCT00814125

AstraZenecaBreast Cancer

Start: 1997-06-30End: 2005-12-31Updated: 2009-05-01

ATAC - Arimidex, Tamoxifen Alone or in Combination

CompletedNCT00849030

AstraZenecaBreast Cancer

Start: 1996-07-31End: 2010-04-30Updated: 2012-06-06

Unknown Phase

Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms

CompletedNCT06982313

Ente Ospedaliero Ospedali GallieraBreast Cancer Invasive

Start: 1996-07-01End: 2026-03-08Target: 1545Updated: 2026-03-11

Related Papers

Low-dose tamoxifen for pre-cancer and early disease: A pooled analysis by menopausal status.

Journal of Clinical Oncology2026-05-27